Clinical Trial Detail

NCT ID NCT03957551
Title Cabozantinib and Pembrolizumab for Advanced Metastatic Melanoma
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Yousef Zakharia
Indications

melanoma

Therapies

Cabozantinib + Pembrolizumab

Age Groups: adult senior

No variant requirements are available.